1. Ferlay, JSI, Ervik, M, Dikshit, R, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 Lyon, France: International Agency for Research on Cancer. 2013 [cited May 23, 2016]. Accessed June 26, 2020. http://globocan.iarc.fr
Google Scholar2. Roehl, KA, Han, M, Ramos, CG, Antenor, JA, Catalona, WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172(3):910–914.
Google Scholar | Crossref | Medline3. Hull, GW, Rabbani, F, Abbas, F, Wheeler, TM, Kattan, MW, Scardino, PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167(2 Pt 1):528–534.
Google Scholar | Crossref | Medline4. Kupelian, PA, Mahadevan, A, Reddy, CA, Reuther, AM, Klein, EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;68(3):593–598.
Google Scholar | Crossref | Medline5. Freedland, SJ, Humphreys, EB, Mangold, LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–439.
Google Scholar | Crossref | Medline6. Baigent, C, Keech, A, Kearney, PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
Google Scholar | Crossref | Medline7. Kashani, A, Phillips, CO, Foody, JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–2797.
Google Scholar | Crossref | Medline8. Mullen, PJ, Yu, R, Longo, J, Archer, MC, Penn, LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16(11):718–731.
Google Scholar | Crossref | Medline9. Harshman, LC, Wang, X, Nakabayashi, M, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495–504.
Google Scholar | Crossref | Medline10. Bonovas, S, Filioussi, K, Sitaras, NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008;123(4):899–904.
Google Scholar | Crossref | Medline11. Kuoppala, J, Lamminpaa, A, Pukkala, E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2122–2132.
Google Scholar | Crossref | Medline12. Dale, KM, Coleman, CI, Henyan, NN, Kluger, J, White, CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74–80.
Google Scholar | Crossref | Medline13. Mass, AY, Agalliu, I, Laze, J, Lepor, H. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol. 2012;188(3):786–791.
Google Scholar | Crossref | Medline14. Bansal, D, Undela, K, D’Cruz, S, Schifano, F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PloS one. 2012;7(10):e46691.
Google Scholar | Crossref | Medline15. Hamilton, RJ, Banez, LL, Aronson, WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2010;116(14):3389–3398.
Google Scholar | Crossref | Medline16. Allott, EH, Howard, LE, Cooperberg, MR, et al. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014;114(5):661–666.
Google Scholar | Crossref | Medline17. Park, HS, Schoenfeld, JD, Mailhot, RB, et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol. 2013;24(6):1427–1434.
Google Scholar | Crossref | Medline18. Scosyrev, E, Tobis, S, Donsky, H, et al. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int. 2013;111(3 Pt B):E71–E77.
Google Scholar | Crossref | Medline19. Tamada, T, Sone, T, Jo, Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging. 2008;28(3):720–726.
Google Scholar | Crossref | Medline20. Hambrock, T, Somford, DM, Huisman, HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453–461.
Google Scholar | Crossref | Medline21. Itou, Y, Nakanishi, K, Narumi, Y, Nishizawa, Y, Tsukuma, H. Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging. 2011;33(1):167–172.
Google Scholar | Crossref | Medline22. Wang, XZ, Wang, B, Gao, ZQ, et al. Diffusion-weighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging. 2009;29(6):1360–1366.
Google Scholar | Crossref | Medline23. Foltz, WD, Wu, A, Chung, P, et al. Changes in apparent diffusion coefficient and T2 relaxation during radiotherapy for prostate cancer. J Magn Reson Imaging. 2013;37(4):909–916.
Google Scholar | Crossref | Medline24. Wang, L, Mazaheri, Y, Zhang, J, Ishill, NM, Kuroiwa, K, Hricak, H. Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology. 2008;246(1):168–176.
Google Scholar | Crossref | Medline25. Roebuck, JR, Haker, SJ, Mitsouras, D, Rybicki, FJ, Tempany, CM, Mulkern, RV. Carr-Purcell-Meiboom-Gill (CPMG) imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging. 2009;27(4):497–502.
Google Scholar | Crossref | Medline26. Gibbs, P, Tozer, DJ, Liney, GP, Turnbull, LW. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn Reson Med. 2001;46(6):1054–1058.
Google Scholar | Crossref | Medline27. Gibbs, P, Liney, GP, Pickles, MD, Zelhof, B, Rodrigues, G, Turnbull, LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44(9):572–576.
Google Scholar | Crossref | Medline28. Nicholson, B, Schaefer, G, Theodorescu, D. Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev. 2001;20(3-4):297–319.
Google Scholar | Crossref | Medline29. Bigler, SA, Deering, RE, Brawer, MK. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 1993;24(2):220–226.
Google Scholar | Crossref | Medline30. Knopp, MV, Giesel, FL, Marcos, H, von Tengg-Kobligk, H, Choyke, P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging. 2001;12(4):301–308.
Google Scholar | Crossref | Medline31. van Dorsten, FA, van der Graaf, M, Engelbrecht, MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20(2):279–287.
Google Scholar | Crossref | Medline32. Longo, J, Hamilton, RJ, Masoomian, M, et al. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020;23(4):630–637.
Google Scholar | Crossref | Medline33. Mason, RP, Walter, MF, Day, CA, Jacob, RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005;96(5A):11F–23F.
Google Scholar | Crossref | Medline34. Longo, J, Mullen, PJ, Yu, R, et al. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Mol Metab. 2019;25:119–130.
Google Scholar | Crossref | Medline35. Chen, C, Lin, J, Smolarek, T, Tremaine, L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos. 2007;35(10):1725–1729.
Google Scholar | Crossref | Medline36. Garwood, ER, Kumar, AS, Baehner, FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119(1):137–144.
Google Scholar | Crossref | Medline37. Weinreb, JC, Barentsz, JO, Choyke, PL, et al. PI-RADS Prostate Imaging–Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16–40.
Google Scholar | Crossref | Medline38. Røe, K, Kakar, M, Seierstad, T, Ree, AH, Olsen, DR. Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study. Radiat Oncol. 2011;6:65.
Google Scholar | Crossref | Medline39. Murtola, TJ, Syvälä, H, Tolonen, T, et al. Atorvastatin versus placebo for prostate cancer before radical prostatectomy-a randomized, double-blind, placebo-controlled clinical trial. Eur Urol. 2018;74(6):697–701.
Google Scholar | Crossref | Medline40. Verma, S, Turkbey, B, Muradyan, N, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol. 2012;198(6):1277–1288.
Google Scholar | Crossref | Medline41. Quantitative IBA . Profile: DCE MRI Quantification: QIBA; 2011 [cited June 29, 2016]. Accessed June 26, 2020. http://qibawiki.rsna.org/images/7/7b/DCEMRIProfile_v1_6-20111213.pdf
Google Scholar42. Reisaeter, LA, Futterer, JJ, Halvorsen, OJ, et al. 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy. Acta Radiol. 2015;56(4):500–511.
Google Scholar | SAGE Journals43. Ullrich, T, Quentin, M, Oelers, C, et al. Magnetic resonance imaging of the prostate at 1.5 versus 3.0 T: a prospective comparison study of image quality. Eur J Radiol. 2017;90:192–197.
Google Scholar | Crossref | Medline44. Bjarnadottir, O, Romero, Q, Bendahl, PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment. 2013;138(2):499–508.
Google Scholar | Crossref | Medline